# Prazosin for Agitation in Alzheimer's Disease

> **NCT03710642** · PHASE2 · COMPLETED · sponsor: **Alzheimer's Disease Cooperative Study (ADCS)** · enrollment: 35 (actual)

## Conditions studied

- Alzheimer's Disease
- Disruptive Behavior

## Interventions

- **DRUG:** Prazosin
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03710642
- **Lead sponsor:** Alzheimer's Disease Cooperative Study (ADCS)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-23
- **Primary completion:** 2022-01-05
- **Final completion:** 2022-01-05
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2023-02-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710642, "Prazosin for Agitation in Alzheimer's Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03710642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*